115 related articles for article (PubMed ID: 29732733)
1. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013.
Pedersen EG; Hallas J; Pottegård A; Hald SM; Jensen PEH; Gaist D
Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):486-493. PubMed ID: 29732733
[TBL] [Abstract][Full Text] [Related]
2. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009.
Pedersen EG; Hallas J; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Feb; 20(2):309-14. PubMed ID: 22882327
[TBL] [Abstract][Full Text] [Related]
3. Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008-2016: A Danish Nationwide Cohort Study.
Haastrup SB; Hellfritzsch M; Rasmussen L; Pottegård A; Grove EL
Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):452-463. PubMed ID: 29664236
[TBL] [Abstract][Full Text] [Related]
4. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2014 Mar; 21(3):454-8. PubMed ID: 24330255
[TBL] [Abstract][Full Text] [Related]
5. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies.
Adelborg K; Grove EL; Sundbøll J; Laursen M; Schmidt M
Heart; 2016 Dec; 102(23):1883-1889. PubMed ID: 27406838
[TBL] [Abstract][Full Text] [Related]
6. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
7. Identifying patients with myasthenia for epidemiological research by linkage of automated registers.
Pedersen EG; Hallas J; Hansen K; Jensen PE; Gaist D
Neuroepidemiology; 2011; 37(2):120-8. PubMed ID: 21986220
[TBL] [Abstract][Full Text] [Related]
8. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study.
Frost A; Svendsen ML; Rahbek J; Stapelfeldt CM; Nielsen CV; Lund T
BMC Neurol; 2016 Nov; 16(1):224. PubMed ID: 27855651
[TBL] [Abstract][Full Text] [Related]
9. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort.
Popperud TH; Boldingh MI; Rasmussen M; Kerty E
Eur J Paediatr Neurol; 2017 Sep; 21(5):707-714. PubMed ID: 28457757
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis in children: a longitudinal study.
Ashraf VV; Taly AB; Veerendrakumar M; Rao S
Acta Neurol Scand; 2006 Aug; 114(2):119-23. PubMed ID: 16867035
[TBL] [Abstract][Full Text] [Related]
11. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
Renoux C; Coulombe J; Suissa S
BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
[TBL] [Abstract][Full Text] [Related]
12. Mortality in myasthenia gravis: A nationwide population-based follow-up study in Denmark.
Hansen JS; Danielsen DH; Somnier FE; Frøslev T; Jakobsen J; Johnsen SP; Andersen H
Muscle Nerve; 2016 Jan; 53(1):73-7. PubMed ID: 25914186
[TBL] [Abstract][Full Text] [Related]
13. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis.
Buzzard KA; Meyer NJ; Hardy TA; Riminton DS; Reddel SW
Muscle Nerve; 2015 Aug; 52(2):204-10. PubMed ID: 25487528
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
[TBL] [Abstract][Full Text] [Related]
15. Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study.
Jeong S; Noh Y; Oh IS; Hong YH; Shin JY
J Korean Med Sci; 2021 Oct; 36(39):e242. PubMed ID: 34636500
[TBL] [Abstract][Full Text] [Related]
16. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark.
Mortensen MB; Falk E; Schmidt M
Circ Cardiovasc Qual Outcomes; 2017 Jul; 10(7):. PubMed ID: 28698192
[No Abstract] [Full Text] [Related]
17. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressant drugs for myasthenia gravis.
Hart IK; Sharshar T; Sathasivam S
J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):5-6; discussion 6. PubMed ID: 19091704
[TBL] [Abstract][Full Text] [Related]
19. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
Wakata N; Nemoto H; Sugimoto H; Nomoto N; Konno S; Hayashi N; Araki Y; Nakazato A
Clin Neurol Neurosurg; 2004 Mar; 106(2):139-41. PubMed ID: 15003307
[TBL] [Abstract][Full Text] [Related]
20. [The continuous treatment of generalized myasthenia gravis with small doses of prednisolone with or wihtout immunosuppressants (author's transl)].
Ichikawa Y; Nakata Y; Koriyama K; Komatsuda M; Arimori S
Nihon Naika Gakkai Zasshi; 1976 Jul; 65(7):669-80. PubMed ID: 988093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
